Graham Cox to join eZono as CEO

JENA, Germany, 6th May 2013 - eZono AG (“eZono”), a private corporation that designs, develops and distributes state of the art tablet ultrasound systems, today announced a leadership transition that will accelerate the company’s growth. eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.

“We are very excited that Graham is bringing his skill, experience and remarkable track record to eZono. I firmly believe that, together with Allan and the team, he will enable the company to realise its enormous potential,” said Hugo Harrod of MVM Life Science Partners, lead investor in eZono.

“Graham is the best candidate for eZono CEO in the world. I’m really happy he will join so we can bring the benefits of our innovative solutions, such as eZono’s groundbreaking needle guidance, to more clinicians and patients across the globe,” commented Allan Dunbar.

“eZono has an impressive and unique team with a proven ability to innovate in the field of portable ultrasound. I am very excited to join the company and take these innovations to market worldwide,” added Graham Cox.

Mr. Cox is an ultrasound industry veteran with more than 35 years of experience in the field. He joins eZono from SonoSite, a recognised leader in point-of-care ultrasound. At Sonosite, he served as Senior Vice President, Worldwide Sales & Distribution. During his 13 year tenure, annual revenues grew from zero to over $250 Million. Prior to joining SonoSite, Mr. Cox also held senior positions running sales and distribution for ATL Ultrasound (now Philips Medical Systems) and Acuson (now Siemens AG). Mr. Cox received an electronic engineer education and holds an Executive MBA (Hon) from the International Management Centers Association.

eZono AG

eZono AG
Portable ultrasound



DownloadPress Release

Latest News

HLS Therapeutics announces Health Canada grants medical device license for CSAN PRONTO

HLS Therapeutics Inc. announces that Health Canada has granted a medical device license for the Athelas One WBC System, marketed as CSAN PRONTO, for use as a point-of-care device indicated for quantitative determination of white blood cells and neutrophil percentages in capillary or venous whole blood.

Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15

Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15.

Baxter Announces Acquisition of Cheetah Medical

Baxter International Inc., a leading global medical products company, today entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies

Zipline announces positive results from two significant clinical studies

ZipLine Medical, Inc. has announced publication of positive results from two significant clinical studies in two peer- reviewed journals demonstrating that use of Zip® Surgical Skin Closure leads to better clinical outcomes and healthcare cost savings than do surgical staples

Valneva reports strong operational performance and major corporate progress with H1 2019 results

Valneva has reported that its H1 2019 results are marked by strong operational performance and major corporate progress; regaining control of key R&D assets and strengthening its financial outlook with $23 million CEPI chikungunya grant

Valneva initiates second Phase II study for its Lyme Disease vaccine candidate

Valneva has announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15